Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

J Immunother Cancer · 2025 · PMC12730848 · PMID 41436232

Europe PMC DOI

hedged sentences

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

showed a trendp=0.12not close (p > 0.1)

Although survival differences among infiltration groups did not reach statistical significance, T-cell infiltrated patients showed a trend toward improved outcomes ( online supplemental figure 2B ; HR=0.31, p=0.12).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

26 Frequencies of CD3+CD8+ cytotoxic T cells and CD3+CD4+ helper T cells appeared elevated in patients with non-high-grade serous (HGS) tumors compared with those with HGS histology ( figure 4C,D ), although this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.